Reconciling IX and Continuous Improvement Organizationally: Not for the Faint at Heart
Industrial Transformation (IX) and Continuous Improvement programs are not easily reconciled. Discover the best practices for Organizational...
TOPIC
IX Platform (3)
Filter by:
The IX Journey: Five Stages of Industrial Transformation (IX)
Explore the five stages of IX maturity and learn why LNS Research believes the Transformation Chasm is the single biggest challenge to IX success.
Rub-A-Dub-Dub...It's All About the Data Hub
Joe Perino defines key terms surrounding Data Hubs, Data Lakes, and Data Architecture and examines some options to consider when architecting the...
My Biggest 2022 Prediction: Guess What Gets A Reset...Again
Check out what prediction– in multiple parts - LNS Research Principal Analyst Tom Comstock is going to make surrounding Industrial Transformation in...
Evaluating Potential Industrial Transformation (IX) Strategic Partners
Revisit our definition of IX Strategic Partners, the criteria used to evaluate vendors, and the list of vendors as we ready our next Solution...
From Lighthouse to Center of Excellence
Drill into when Lighthouse strategies can be effective and why a Center of Excellence strategy can be correlated more to success with Analysts Tom...
The “Holy Grail” and the “Puzzle” in Discrete and Batch Manufacturing Applications
Principal Analyst Tom Comstock navigates the Puzzle manufacturers face in Discrete and Batch Manufacturing searching for the Holy Grail of computing...
EHS Transformation Starts with Effective Leadership
Learn why a successful EHS Transformation starts with Effective Leadership, and how IX is a major opportunity for EHS leaders to drive performance...
Survey Snippets #3: The Evolution of Industrial Transformation (IX) Leaders
LNS Research Associate Vivek Murugesan examines the evolution of Industrial Transformation (IX) among leaders, moving from digital transformation to...
Should Pharma Regain MES Leadership or Become the New IX Leaders?
Principal Analyst, Andrew Hughes, discusses the choice pharma companies need to make: regain their leadership in MES or become the new leaders in IX